Sirs,

We thank Dr Martínez-Vidal et al. for their interest in our work “Reclassification into very-high cardiovascular risk after carotid ultrasound in patients with axial spondyloarthritis” (1). In the letter submitted by Martínez-Vidal et al. it is presented that, in a series of patients with psoriatic arthritis (PsA) recruited by these authors, carotid plaque was present in 30.7%, and as much as 30.1% were reclassified into the very high-risk SCORE group according to carotid ultrasound. They, therefore, argue that in PsA patients, similarly to what we have described in axial spondyloarthritis (axSpA) (1), carotid ultrasound assessment would be of benefit in stratifying patients into its correct SCORE risk category.

The data presented by Martínez-Vidal et al. support the concept that inflammatory arthritides are poorly and incorrectly classified according to cardiovascular risk charts used in general populations. Moreover, carotid ultrasound assessment could be a useful tool to determine this risk more accurately. This has been extensively established in several publications of our group in patients with rheumatoid arthritis (2, 3) and systemic lupus erythematosus (4). Moreover, in a recent report of our group in PsA patients (5), we have demonstrated, as Martínez-Vidal et al. does, that these patients are more frequently reclassified into the very-high SCORE risk category following carotid ultrasound assessment than controls. However, in our report we did not fail to find an association between reclassification and the activity of the disease. In this sense, in our study (5), we consistently found that Disease Activity in Psoriatic Arthritis (DAPSA) score was significantly associated with reclassification after adjusting for age and traditional cardiovascular risk factors. Furthermore, a model containing SCORE plus age, statin use, and DAPSA score yielded a higher discriminatory accuracy compared to the SCORE alone model to determine the probability of reclassification (5).

Finally, we reiterate our thanks to Martínez-Vidal et al. for their letter information regarding patients with PsA. Their data support our findings and strengthen the concepts detailed in our manuscript. We also believe that future works will yield more information in this topic and will sustain similar conclusions regarding subclinical atherosclerosis in inflammatory diseases.

I. Ferraz-Amaro, MD, PhD
J. Rueda-Gotor, MD, PhD
M.A. González-Gay, MD, PhD
1Division of Rheumatology, Hospital Universitario de Canarias, Tenerife, Spain; 2Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, Santander, Spain.

Please address correspondence to:
Iván Ferraz-Amaro,
Division of Rheumatology,
Hospital Universitario de Canarias,
Ofra s/n, 38320 Santa Cruz de Tenerife, Spain.
E-mail: iferrazamoro@hotmail.com

Competing interests: none declared.

© Copyright CLINICAL AND EXPERIMENTAL RHEUMATOLOGY 2020.

References